Learn the key signs CLL is getting worse, including constitutional B-symptoms and lymphocyte doubling time, to help identify when to discuss treatment options.

In clinical settings, you’ll often hear your care team use the shorthand R/R, standing for relapsed/refractory. This term covers patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who either saw their disease return after a period of remission or whose CLL never adequately responded to treatment in the first place. The term “relapsed/refractory” is frequently used […]

When standard treatments for chronic lymphocytic leukemia (CLL) stop working, patients face important decisions about what comes next. In our recent webinar, Stanford University’s Dr. Bita Fakhri highlights how emerging approaches, from next-generation BTK inhibitors to CAR T-cell therapy, are offering new hope for this population. Watch the full webinar The following questions and responses […]

Treatment options for chronic lymphocytic leukemia (CLL) are highly individualized. Your care team considers several key elements when designing your treatment plan, and clinical scientist and CLL expert Dr. Bita Fakhri highlights three of the most important: the characteristics of the leukemia itself, the patient’s overall health and preferences, and the potential risks and benefits […]

After a chronic lymphocytic leukemia (CLL) diagnosis, you may hear about treatment options including watchful waiting, chemotherapy, targeted therapy, or immunotherapy. Asking your care team about clinical trials may provide additional ways to explore innovative therapies and treatment strategies. In CLL, clinical trials are driving advances in targeted therapy, combination regimens, and precision medicine approaches […]